Expanding Accessibility In A Phase 3 Influenza Study Through Community-Based Research

This ongoing Phase 3 study demonstrates how community-based research can transform vaccine trials by improving diversity, accessibility, and retention. Focused on evaluating a novel seasonal influenza vaccine in adults aged 50 and older, the trial addresses two persistent challenges in clinical research: the underrepresentation of minority populations and low participant retention.

To overcome these barriers, EmVenio Clinical Research deployed a community-based model that integrates mobile research units and localized study sites to bring clinical trials directly to patients. Additionally, by establishing research sites within underserved U.S. communities, EmVenio dramatically improved representation—enrolling more than three times the industry average of African American/Black participants and achieving a 99% retention rate.

The results highlighted in this study show the potential of decentralized, patient-centered research models to enhance engagement, reduce disparities, and strengthen data quality. By meeting participants where they are, this study sets a new benchmark for inclusive, efficient, and impactful vaccine development.